Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
Status:
Terminated
Trial end date:
2019-06-03
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the efficacy of Cannabidiol Oral Solution in
the treatment of pediatric participants with treatment-resistant childhood absence seizures.
This study will also assess safety, tolerability and pharmacokinetics of Cannabidiol Oral
Solution, and any improvement in qualitative assessments of participant status over the
duration of the study in pediatric participants with treatment-resistant childhood absence
seizures. The study will include a 4-week Screening Period, a 5 or 10 day Titration Period
(depending study Cohort), a 4-week Treatment Period followed by 5-day Tapering for doses >20
mg/kg/day and a 4-week Follow-up Period.